Abstract: Described herein are nanoprobes comprising ultrasmall aminated and cRGDY-conjugated nanoparticles labeled with Zirconium-89 (89Zr) and methods of their use. The provided compositions are renally clearable and possess suitable blood circulation half-time, high tumor active targeting capability, dominant renal clearance, low liver accumulation, and a high tumor-to-background ratio. The described nanoprobes exhibit great potential as “target-or-clear” tracers to human subjects for systemic targeted imaging (or treatment) of cancer.

Abstract: The invention relates to a novel radiopharmaceutical that inhibits the prostate-specific membrane antigen (iPSMA), containing hydrazinonicotinamide (HYNIC) as a critical chemical group in increasing in the lipophilicity of the molecule for binding to the hydrophobic sites of the PSMA, combined with the conventional use of HYNIC as a chelating agent for radiometal 99mTc, in which the ethylenediaminetetraacetic acid (EDDA) is used to complete the coordination sphere of the radiometal. The novel radiopharmaceutical 99mTc-EDDA/HYNIC-iPSMA detects, with high affinity and sensitivity in vivo, the overexpressed PSMA protein in prostate cancer cells using SPECT molecular imaging techniques in nuclear medicine. The aim of the invention is to provide a novel specific radiopharmaceutical (radiopharmaceutical for molecular targets) for SPECT, with high sensitivity for the detection of tumours with overexpression of PSMA.

Abstract: Provided herein are compositions and methods for stabilizing coelenterazine and analogs or derivatives thereof, and for improving the solubility and reconstitution efficiency of coelenterazine and analogs and derivatives thereof.

Abstract: Methods of ex vivo labeling of a biological material for in vivo imaging, methods of labeling a biological material in vivo, methods for preparing a labeling agent, and methods for in vivo imaging of a subject using a biological material labeled with a labeling agent are disclosed. In one non-limiting example, the biological material is selected from cells and the labeling agent is a 89Zr-Desferrioxamine-NCS labeling agent.

Abstract: The present invention relates to an emulsion composition for chemoembolization comprising a nanoparticle comprising a drug and a biocompatible polymer, a water-soluble contrast agent and a water-insoluble contrast agent, and a water-insoluble drug as well as an aqueous drug can be administered in a form of stable emulsion, and drugs are slowly released, thereby enhancing the effect of chemoembolization.

Abstract: The invention relates to a novel use of ultrafine nanoparticles, of use as a diagnostic, therapeutic or theranostic agent, characterized by their mode of administration via the airways. The invention is also directed toward the applications which follow from this novel mode of administration, in particular for imaging the lungs, and the diagnosis or prognosis of pathological pulmonary conditions. In the therapeutic field, the applications envisioned are those of radiosensitizing or radioactive agents for radiotherapy (and optionally curietherapy), or for neutron therapy, or of agents for PDT (photodynamic therapy), in particular for the treatment of lung tumors.

Abstract: Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.

Abstract: Provided herein are methods and materials that allow targeting and imaging of interactions between probes and targets. In some embodiments, the probes include nanoscale materials with embedded solutions that can be used to measure physical enhancement by materials under X-ray irradiation. In some embodiments, the methods of the present invention include delivering a probe material to a target that can have a delivered donor material. In some embodiments, methods of the present invention include irradiating the target and determining an optical change in the probe characteristic of a physical enhancement.

Abstract: In one aspect, the invention comprises compounds that bind to the synaptic vesicle protein SV2A and that can be useful as radiotracers for positron emission tomography. In another aspect, the invention comprises methods of imaging the brain, measuring synaptic density or diagnosing neurological diseases such as Alzheimer's disease, psychiatric disorders such as depression, and metabolic disorders such as diabetes comprising detecting the compounds of the invention by positron emission tomography (PET).

Abstract: The present invention relates to methods of forming metal-pyridine derivative complexes using pericyclic reactions with metal-1,2,4-triazine derivative complexes and a dienophile as the reactants. The reactants are bioorthogonal and the methods are particularly useful in preparing imaging agents.

Abstract: The invention relates to amphiphilic dye-coated inorganic nanoparticle clusters and uses thereof. Specifically, the invention relates to cyanine and/or cyclic tetrapyrrole dye-coated metallic nanoparticle clusters for use in medical imaging and treatments.

Abstract: The present invention is related to short-term renal injury models and methods for creating these models. The models and methods can be used for identifying, testing or characterizing candidate molecules with respect to their suitability to treat renal injury. The methods comprise a step of inducing, in a test subject, renal injury by administering subcutaneously a bolus of a renal injury inducer, in a dosage sufficiently high to induce renal injury. Different types of readout for renal injury are provided such as albumin creatinine ratio (ACR) determined in a urine sample taken from the subject, or the development of transcutaneous fluorescence after injection of a fluorescent molecule. Based on the readout the degree of renal injury and/or alteration of GFR can be determined.

Abstract: Provided is a microsphere including a glass sphere core. The glass sphere core includes a first nuclide, a second nuclide and a diffusion region extending inwardly from an outer surface of the glass sphere core, with the second nuclide distributed in the diffusion region. The first nuclide and the second nuclide become radioactive after being activated by neutrons to produce radiations including ?-rays or ?-rays, or simultaneously ?-rays and ?-rays. A preparation method of a microsphere is also provided.

Abstract: The subject matter of the invention is PSMA inhibitor-HYNIC derivatives of PSMA-L1-L2-HYNIC formula, aromatic and aliphatic hydrazone derivatives, a radiopharmaceutical kit for 99mTc isotope labelling, radiopharmaceutical preparation and its application for prostate cancer and its metastasis diagnostics.

Abstract: A method for early stage pathology detection, location, imaging, evaluation, and treatment of cells and/or extracellular vesicles in the circulation.

Abstract: Gadolinium based contrast agents (GCA) incorporating linear ligand chelation are fundamentally different from GCAs incorporating macrocyclic ligands. The macrocyclic\GCAs are synthesized by pathways characterized by the formation of a sequence of metastable complexes before obtaining the final stable complex. The synthesis of linear GCAs do not form metastable complexes. Commercial macrocyclic GCAs contain unstable metastable complexes. These metastable species are not regulated and quickly release free Gd3+ ions upon administration into the body. Gadolinium based contrast agents with near zero metastable species content and methods of synthesizing the same are disclosed. Gadolinium based contrast agents with long dissociation time in the body, and low free Gd3+ ion formation are obtained using a synthesis method which departs in novel ways from the traditional free Gd3+-based synthesis methods.

Abstract: The present disclosure provides compositions and methods for the treatment of cancer. Specifically, the compositions of the present technology include novel clearing agents that may be used in pretargeted radioimmunotherapy.

Abstract: A method for manufacturing supported lipid bilayer on a porous silica nanoparticle with a ?-potential comprised between ?10 mV and +10 mV, the method comprising the steps of (a) providing a negatively charged supported lipid bilayer on a porous silica nanoparticle, wherein the negatively charged supported lipid bilayer has a ?-potential inferior to ?15 mV and wherein the negatively charged supported lipid bilayer comprised at least one phospholipid and; (b) adding a formulation of lipids, the lipids being 1,2-dioleoyl-3-trimethylammonium-propane alias DOTAP, cholesterol and at least one lipid different from DOTAP and cholesterol. The method further comprises the step of (c) performing an ultra-sonication for promoting DOTAP incorporation. The method can be supplemented by the step of addition of alginate and the step of cross-linking the alginate. Also a nanocapsule and composition comprising the nanocapsule.

Abstract: Methods, systems and computer-accessible medium for imaging a living cell or a living organism with bond-edited compounds using stimulated Raman scattering are disclosed. The method comprises the steps of introducing one or more bond-edited compounds into a live cell or a living organism, and detecting a vibrational tag in the cell or organism with stimulated Raman scattering. Also disclosed are methods for detecting a disease condition in a subject, methods for monitoring treatment for a disease condition, methods for screening an agent, methods for tracing a cellular process in a live cell using bond-edited compounds in combination with stimulated Raman scattering. Also disclosed are a composition for labeling a target cell with at least one bond-edited compound and devices for imaging bond-edited compounds by stimulated Raman scattering.

Abstract: The present invention is directed to a method for identifying ductal leaks during pancreobiliary surgery in a human patient. The invention comprises the steps of: administering to a human patient undergoing pancreobiliary surgery an effective amount of a pharmaceutical composition comprising secretin and a pharmaceutically acceptable carrier; and observing the patient during the surgery for the presence of pancreobiliary ductal leaks.